Neomycin Polymyxin B Sulfates And Dexamethasone

Neomycin Sulfate, Polymyxin B Sulfate And Dexamethasone


Bausch & Lomb Incorporated
Human Prescription Drug
NDC 24208-830
Neomycin Polymyxin B Sulfates And Dexamethasone also known as Neomycin Sulfate, Polymyxin B Sulfate And Dexamethasone is a human prescription drug labeled by 'Bausch & Lomb Incorporated'. National Drug Code (NDC) number for Neomycin Polymyxin B Sulfates And Dexamethasone is 24208-830. This drug is available in dosage form of Suspension/ Drops. The names of the active, medicinal ingredients in Neomycin Polymyxin B Sulfates And Dexamethasone drug includes Dexamethasone - 1 mg/mL Neomycin Sulfate - 3.5 mg/mL Polymyxin B Sulfate - 10000 [USP'U]/mL . The currest status of Neomycin Polymyxin B Sulfates And Dexamethasone drug is Active.

Drug Information:

Drug NDC: 24208-830
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Neomycin Polymyxin B Sulfates And Dexamethasone
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Neomycin Sulfate, Polymyxin B Sulfate And Dexamethasone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Bausch & Lomb Incorporated
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Suspension/ Drops
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DEXAMETHASONE - 1 mg/mL
NEOMYCIN SULFATE - 3.5 mg/mL
POLYMYXIN B SULFATE - 10000 [USP'U]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:OPHTHALMIC
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 13 Sep, 1995
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 19 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA064135
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Bausch & Lomb Incorporated
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:309680
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0324208830604
UPC stands for Universal Product Code.
NUI:N0000175576
N0000175450
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:7S5I7G3JQL
057Y626693
19371312D4
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:Corticosteroid Hormone Receptor Agonists [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:Corticosteroid [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class:Aminoglycoside Antibacterial [EPC]
Aminoglycosides [CS]
Corticosteroid Hormone Receptor Agonists [MoA]
Corticosteroid [EPC]
Polymyxin-class Antibacterial [EPC]
Polymyxins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
24208-830-601 BOTTLE, DROPPER in 1 CARTON (24208-830-60) / 5 mL in 1 BOTTLE, DROPPER13 Sep, 1995N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Neomycin polymyxin b sulfates and dexamethasone neomycin sulfate, polymyxin b sulfate and dexamethasone neomycin sulfate neomycin polymyxin b sulfate polymyxin b dexamethasone dexamethasone sodium chloride polysorbate 20 water hydrochloric acid sodium hydroxide benzalkonium chloride hypromellose, unspecified

Indications and Usage:

Indications and usage for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia c
oli , haemophilus influenzae, klebsiella/enterobacter species, neisseria species, and pseudomonas aeruginosa. this product does not provide adequate coverage against: serratia marcescens and streptococci, including streptococcus pneumoniae.

Warnings:

Warnings not for injection. use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perfor
ation. if this product is used for 10 days or longer, intraocular pressure (iop) should be routinely monitored even though it may be difficult in children and uncooperative patients. steroids should be used with caution in the presence of glaucoma. iop should be checked frequently. the use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension is not for injection. it should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye. products containing neomycin sulfate may cause cutaneous sensitization. sensitivity to topically administered aminoglycosides, such as neomycin, may occur in some patients. severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. if hypersensitivity develops during use of the product, treatment should be discontinued. cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.

General Precautions:

General the initial prescription and renewal of the medication order beyond 20 ml of neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining. if signs and symptoms fail to improve after two days, the patient should be reevaluated. as fungal infections of the cornea are particularly prone to develop coincidentally with long-term corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. fungal cultures should be taken when appropriate. if this product is used for 10 days or longer, iop should be monitored ( see warnings ). prolonged use of topical anti-bacterial agents may give rise to overgrowth of non-susceptible organisms including fungi.

Dosage and Administration:

Dosage and administration one to two drops in the conjunctival sac(s). in severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides. in mild disease, drops may be used up to four to six times daily. not more than 20 ml should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in precautions above.

Contraindications:

Contraindications neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

Adverse Reactions:

Adverse reactions adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. exact incidence figures are not available since no denominator of treated patients is available. reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations. the reactions due to the corticosteroid component are: elevation of iop with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. corticosteroid-containing preparations have also been reported to cause perforation of the globe. keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following use of steroids. additional adverse reactions identified from post marketing use include ulcerative keratitis, headache, and stevens-johnson syndrome. the fo
llowing additional adverse reactions have been reported with dexamethasone use: cushing’s syndrome and adrenal suppression may occur after use of dexamethasone in excess of the listed dosing instructions in predisposed patients, including children and patients treated with cyp3a4 inhibitors. to report suspected adverse reactions, contact bausch & lomb incorporated at 1-800-553-5340 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Use in Pregnancy:

Pregnancy dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose. in the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. in the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc. there are no adequate or well-controlled studies in pregnant women. however, prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation. neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.

Pediatric Use:

Pediatric use safety and effectiveness in pediatric patients below the age of 2 years have not been established.

Geriatric Use:

Geriatric use no overall differences in safety or effectiveness have been observed between elderly and younger patients.

Description:

Description neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension, usp is a multiple dose anti-infective steroid combination in sterile suspension form for topical application. the chemical structure for the active ingredient, dexamethasone, is: established name: dexamethasone chemical name: pregna-1, 4-diene-3, 20-dione, 9-fluoro-11,17, 21-trihydroxy-16-methyl-, (11β,16α)-. the other active ingredients are neomycin sulfate and polymyxin b sulfate. the structural formula for neomycin sulfate is: the structural formula for polymyxin b sulfate is: each ml contains: actives: neomycin sulfate equivalent to neomycin 3.5 mg, polymyxin b sulfate 10,000 units, dexamethasone 0.1%. inactives: hypromellose 2910 0.5%, sodium chloride, polysorbate 20, hydrochloric acid and/or sodium hydroxide (to adjust ph), purified water, benzalkonium chloride 0.004% (preservative). chem chem1 chem2

Clinical Pharmacology:

Clinical pharmacology corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. since corticosteroids may inhibit the body’s defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case. when a decision to administer both a corticosteroid and an antimicrobial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered, plus assured compatibility of ingredients when both types of drugs are in the same formulation and, particularly, that the correct volume of drug is delivered and retained. the relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin b sulfate. treatment of cultured human lymphocytes in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 mcg/ml) tested. however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown. polymyxin b has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.

How Supplied:

How supplied neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension, usp is supplied as a sterile ophthalmic suspension in a white, low-density polyethylene (ldpe) bottle with a linear low-density polyethylene (lldpe) extended controlled drop tip and polypropylene cap: ndc 24208-830-60 - 5 ml in 10 ml bottle storage: store between 15°c to 25°c (59°f to 77°f). store upright. keep out of reach of children. distributed by: bausch & lomb americas inc. bridgewater, nj 08807 usa manufactured by: bausch & lomb incorporated tampa, fl 33637 usa © 2022 bausch & lomb incorporated or its affiliates rev. 12/2022 9114206 (folded) 9114306 (flat)

Information for Patients:

Information for patients if inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician. this product is sterile when packaged. to prevent contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. the use of this bottle by more than one person may spread infection. keep bottle tightly closed when not in use. keep out of reach of children. patients should be advised that their vision may be temporarily blurred following dosing with neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension. care should be exercised in operating machinery or driving a motor vehicle.

Package Label Principal Display Panel:

Principal display panel ndc 24208-830-60 neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension, usp (sterile) for topical ophthalmic use only. rx only 5 ml bausch + lomb 9531903 ab04107 carton


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.